|Bid||0.0000 x 1200|
|Ask||0.0000 x 3100|
|Day's range||1.3400 - 1.4700|
|52-week range||1.0000 - 28.4900|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Earnings date||13 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.